Summary:

By increasing research, development, and clinical activities throughout the nation, Novartis is bolstering India's position in its worldwide drug development strategy. Participation in international drug development initiatives is made possible by India's emergence as a major center for scientific talent, digital skills, and advanced research support. In order to support clinical research, data analytics, AI-enabled research, and regulatory operations throughout the drug development lifecycle, the company hires scientists, data specialists, and IT professionals in India. Novartis emphasized that pharmaceutical innovation is being accelerated and global healthcare outcomes are being improved by India's robust talent ecosystem and expanding digital infrastructure. With the help of highly qualified personnel, cost competitiveness, and biotechnology know-how, India is also becoming a hub for biomedical research, AI-driven drug discovery, and digital healthcare technologies, bolstering its position in the global pharmaceutical industry.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.